Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
|
US |
|
Bleecker SA
PAR:BLEE
|
FR |
|
B
|
Baidu Inc
XMUN:B1CB
|
CN |
|
Altitude Minerals Ltd
ASX:ATT
|
AU |
|
T
|
TDSPharm Co Ltd
KOSDAQ:464280
|
KR |
|
R
|
Rockworth PCL
SET:ROCK
|
TH |
|
Reliance Worldwide Corporation Ltd
F:0EU
|
AU |
Intrinsic Value
Is RYTM undervalued or overvalued?
See the intrinsic value estimate for
Rhythm Pharmaceuticals Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Rhythm Pharmaceuticals Does
Rhythm Pharmaceuticals is a biopharmaceutical company that focuses on rare genetic diseases that cause severe obesity. Its main product is Imcivree, a prescription medicine used for certain patients whose body’s appetite-control pathway does not work properly. The company also develops follow-on treatments aimed at the same biology, especially the melanocortin-4 receptor pathway that helps regulate hunger and body weight.
- Headquarters
- United States of America US
- Employees
- 414
- IPO date
- Oct 5, 2017
Revenue & Expenses Breakdown
Rhythm Pharmaceuticals Inc
Earnings Waterfall
Rhythm Pharmaceuticals Inc
The intrinsic value for
Rhythm Pharmaceuticals Inc (RYTM) under the Base Case is hidden USD.
Compared with the current market price of 104.545 USD, the stock appears hidden.